EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP-1 receptor agonists in the management of obesity: Metabolic and cardiovascular benefits beyond weight loss

Marina Knebel Bacchieri, Inara Lúcia Marques De Sousa, Fernanda Ceron Damiani, Felipe Costa Soares

International Health Sciences Review · 17.03.2026 · 2 (2)

DOI: 10.70164/ihsr.v2i2.137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 17.03.2026. Verfasst von Marina Knebel Bacchieri und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity has historically been managed through a lens of adiposity reduction, primarily focusing on caloric restriction and physical activity. However, the emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has facilitated a fundamental transition toward a comorbidity-centric approach, emphasizing the mitigation of multi-organ dysfunction. This literature review analyzes the systemic impacts of semaglutide, tirzepatide, and emerging therapies like retatrutide. Through a comprehensive evaluation of landmark clinical trials including STEP, SELECT, FLOW, and SURMOUNT, it is demonstrated that GLP-1RAs exert profound pleiotropic effects on cardiovascular stability, renal preservation, and hepatic metabolic health. Key findings indicate that cardiovascular benefits, such as the 20% reduction in major adverse cardiovascular events (MACE) observed in the SELECT trial, occur largely independently of the magnitude of weight loss (Lincoff et al., 2023). Furthermore, the stabilization of renal function and resolution of metabolic dysfunction-associated steatohepatitis (MASH) suggest that these agents function as systemic disease-modifying stabilizers. The paradigm shift from weight loss medications to essential cardiometabolic stabilizers is supported by robust evidence, establishing a new gold standard for clinical decision-making in obesity management.

Zitieren

APA

Bacchieri, M. K., Sousa, I. L. M. D., Damiani, F. C., & Soares, F. C. (2026). GLP-1 receptor agonists in the management of obesity: Metabolic and cardiovascular benefits beyond weight loss. International Health Sciences Review, 2(2). https://doi.org/10.70164/ihsr.v2i2.137

Vancouver

Bacchieri MK, Sousa ILMD, Damiani FC, Soares FC. GLP-1 receptor agonists in the management of obesity: Metabolic and cardiovascular benefits beyond weight loss. International Health Sciences Review. 2026;2(2). doi:10.70164/ihsr.v2i2.137

BibTeX
@article{Bacchieri2026,
  author = {Bacchieri, Marina Knebel and Sousa, Inara Lúcia Marques De and Damiani, Fernanda Ceron and Soares, Felipe Costa},
  title = {GLP-1 receptor agonists in the management of obesity: Metabolic and cardiovascular benefits beyond weight loss},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.70164/ihsr.v2i2.137}
}
Kostenlos starten →